Carb Fence
Pre-clinical- Indications
- Prediabetes, Diabetes
Company intelligence / Profile preview
Sigrid’s lead product candidates based on its proprietary SiPore® platform have demonstrated significant reductions in blood sugar spikes, HbA1c levels, LDL cholesterol and body fat composition. Clinical research shows users with type 2 diabetes saw a larger HbA1c reduction compared to metformin in half the time. The company has completed four clinical trials to date.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sigrid Therapeutics.